(NASDAQ: CLDX) Celldex Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.92%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 35.94%.
Celldex Therapeutics's earnings in 2026 is -$258,757,000.On average, 16 Wall Street analysts forecast CLDX's earnings for 2026 to be -$316,629,481, with the lowest CLDX earnings forecast at -$344,440,901, and the highest CLDX earnings forecast at -$257,212,361. On average, 16 Wall Street analysts forecast CLDX's earnings for 2027 to be -$318,699,695, with the lowest CLDX earnings forecast at -$385,538,963, and the highest CLDX earnings forecast at -$230,652,389.
In 2028, CLDX is forecast to generate -$212,246,794 in earnings, with the lowest earnings forecast at -$384,886,613 and the highest earnings forecast at -$108,336,728.